RIVOROXABAN IN PATIENTS WITH TYPE I ATRIAL FLUTTER: EFFECTIVENESS, SAFETY AND COMPLIANCE

Aim. To assess effectiveness, safety and adherence to treatment of patients with type I atrial flutter who were previously excluded from the clinical trials evaluating the potential benefits of rivoroxaban for thromboembolism prevention.

Methods. 27 medical records of patients with type I atrial flutter were retrospectively reviewed and assigned to the study group. The control group consisted of 100 patients with atrial fibrillation. Both groups received rivoroxaban. All patients underwent thromboembolism risk assessment with the CHA2DS2-VACs score, bleeding risk assessment with HAS-BLED score. Data were collected by telephone.

Results. No thromboembolic events were registered in the atrial flutter group, whereas one case of ischemic stroke was in the atrial fibrillation group. There were no major bleedings in both groups. Four patients with atrial flutter and 2 patients with atrial fibrillation had hemorrhages. Patients’ adherence to rivoroxaban was 75–80%.

Conclusion. Rivoroxaban therapy was found to be effective and safe in patients with type I atrial flutter including those who underwent cardioversion. High adherence to rivoroxaban therapy was demonstrated.

1. Ardashev A.V., Zhelyakov E.G., Pokushalov E.A., Turov A.N., Shavarov A.A. Trepetanie predserdii` i initcizionny`e tahikardii v kn. pod red. Ardasheva A.V. Clinicheskaia aritmologiia. Moscow; 2009. гл.36, p. 860-944. (in Russian)

2. Zatei`shchikov D.A., Zotova I.V., Dankovtceva E.N., Sidorenko B.A. Trombozy` i antitromboticheskaia terapiia pri aritmiiakh. 2 nd ed. Moscow; 2011. p. 94 (in Russian)

3. Biblo L.A., Yuan Z., Quan K.J., Mackall J.A., Rimm A.A. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001; 87:346-49

4. Transesophageal echocardiografic correlates of tromboembolism in high-risk patients with nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med .1998; 128: 639-47

5. Irani W.N., Graybern P.A., Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: a prospective study using transesophageal echocardiografy. Circulation. 1997; 95: 962-66

6. Khan I.A. Transientatrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. Am Heart J. 2002; 144(1): 11-22

7. S.V. Moiseev. Priverzhennost` k antikoaguliantnoi` terapii: problemy` i puti resheniia. Clinicheskaia farmakologiia i terapiia. 2014; 23 (4): 23-28. (in Russian)

8. Bosworth H.B., Granger B.B., Mendys P., Brindis R., Burkholder R., Czajkowski S.M. et al. Medication adherence: A call for action. Am Heart J. 2011,162:412–24.

9. World Health Organization [Internet]: Adherence to long-term therapies: evidence for action. 2010. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/

10. Moiseev S.V. Kak uluchshit` priverzhennost` k dvoi`noi` antitrombotcitar- noi` terapii posle ostrogo koronarnogo sindroma? Clinicheskaia farmakologiia i terapiia. 2011;20(4):34-40 (in Russian)

11. Reynolds M.W., Fahrbach K., Hauch O., Wygant G., Estok R., Cella C., Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126(6):1938-45

12. Gallagher A.M., Setakis E., Plumb J.M., Clemens A., van Staa T.P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Tromb heamost, 2011; 106: 968-77. oi: 10.1160/TH11-05-0353

13. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.

14. Laliberte F., Nelson W.W., Lefebvre P., Schein J.R., Rondeau-Leclaire J., Duh M.S. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29:675–90.

15. Coleman C.I., Roberts M.S., Sobieraj D.M., Lee S., Alam T., Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012; 28(5):669–80.

16. Zamorano J.L., Greiner W., Sandberg A., Oberdiek A.M., Bakhai A. Patient preferences for chronic treatment for stroke prevention: results from the EUropean Patients survey in Atrial Fibrillation (EUPS-AF). Proceedings of the Annual Congress of the European Society of Cardiology; 2012 Aug 2529; Munich, Germany.

17. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et al Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638

18. Cappato R., Ezekowitz M.D., Klein A.L., Camm A.J., Ma C.S., Le Heuzey J.Y. et. al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367

19. Haas S., Bode C., Norrving B., Turpie A.G. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag. 2014 Mar 10;10:101-14. doi: 10.2147/VHRM.S55246

20. Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D. et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116:180–7. DOI: 10.1161/CIRCULATIONAHA.106.668020

21. Diamantopoulos А., Forster F., Evers T. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. ESC Congress. 2013; poster P519.

22. Nelson W.W., Song Х., Coleman C.I., Thomson Е., Smith D.M., Damaraju C., Schein J. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014 Dec; 30(12):2461-9. doi: 10.1185/03007995.2014.933577

23. Laliberte F., Bookhart B.K., Nelson W.W., Lefebvre P., Schein J.R., Rondeau-Leclaire J., Duh M.S. Impact of OnceDaily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism. Patient. 2013; 6(3):213–224. doi: 10.1007/ s40271-013-0020-5.

24. Beyer-Westendorf J., Förster K., Ebertz F., Gelbricht V., Schreier T., Göbelt M., Michalski F., Endig H., Sahin K., Tittl L., Weiss N. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015 Apr;17(4):530-8 doi: 10.1093/europace/euu319

25. Diagnostika i lechenie fibrilliatcii predserdii`. Rekomendatcii RKO, VNOA I ASS. Rossijskij kardiologicheskij zhurnal. 2013; 18 (4 S3): 1-100. (in Russian)

26. Iunkerov V.I., Grigor`ev S.G. Matematikostatisticheskaia obrabotka danny`kh meditcinskikh issledovanii` - Sankt-Peterburg: VmedA ; 2002. (in Russian)